Having secured financing from Novo Seeds in December 2020, Hemab Therapeutics has completed a sizeable $55m series A round led by a trio of blue-chip investment funds. The biotech will use the financing to advance its pipeline of bi-specific, prophylactic monoclonal antibodies targeting underserved bleeding and thrombosis disorders.
In contrast to the progress seen in hemophilia A and B, the rare disorders that Hemab is targeting, such as Glanzmann’s thrombasthenia, have been overlooked for decades. Patients of these...